Monday, May 23, 2022
    HomeHealthSTAT+: Pharmalittle: Senate committee advances Califf FDA nomination; bedraggled Biogen writes a...

    STAT+: Pharmalittle: Senate committee advances Califf FDA nomination; bedraggled Biogen writes a shopping list



    And so, one other working week will quickly draw to an in depth. Not a second too quickly, sure? That is, you might recall, our treasured sign to daydream about weekend plans. Our agenda is quite modest. We plan to promenade with the official mascot and atone for our studying. There’s additionally paperwork to be performed and the annual hunt for a trusty shovel hiding within the software shed. And what about you? It is a high quality time to cozy up with an excellent e-book or in entrance of the telly. You might buy groceries earlier than costs rise once more. Or you might persuade somebody to get vaccinated. Properly, no matter you do, have a grand time. However be secure. Take pleasure in, and see you Tuesday, since there’s an prolonged break on this facet of the pond. …

    Determined to reverse the turmoil surrounding its controversial Alzheimer’s therapy Aduhelm, Biogen (BIIB) has a procuring record of potential acquisitions, STAT studies. And the corporate’s risk-averse board, which has repeatedly rejected potential offers, may very well be more and more receptive. The corporate, whose inventory worth is down almost 50% since Aduhelm’s June approval, is working with Goldman Sachs to seek out potential buyout targets The funding financial institution has offered Biogen with an inventory of smaller biotech firms that may match with the corporate’s deal with neuroscience, though Biogen has not approached any of the businesses a few deal.

    Continue to STAT+ to read the full story…


    Source link

    Related articles

    Stay Connected


    Latest posts